Iron Deficiency Anemia Therapy

Introduction / Overview

Iron deficiency anemia (IDA) constitutes the most prevalent form of anemia worldwide and is frequently encountered in clinical practice across all age groups. The condition arises from an inadequate supply of iron relative to the demands of erythropoiesis, leading to impaired hemoglobin synthesis, reduced oxygen-carrying capacity, and consequent clinical manifestations such as fatigue, pallor, dyspnea, and diminished functional status. The therapeutic approach to IDA is largely pharmacologic, comprising oral and intravenous iron preparations, each with distinct pharmacodynamic and pharmacokinetic properties that influence efficacy, tolerability, and patient adherence. A comprehensive understanding of these agents is essential for clinicians and pharmacists to optimize treatment regimens, minimize adverse events, and improve health outcomes. The following chapter outlines key aspects of iron deficiency anemia therapy, including drug classification, mechanisms of action, pharmacokinetics, clinical applications, safety considerations, drug interactions, and special patient populations.

Learning Objectives

• Describe the pharmacologic spectrum of iron preparations used in IDA therapy.
• Explain the cellular and molecular mechanisms underlying iron absorption and distribution.
• Compare the pharmacokinetic profiles of oral versus intravenous iron formulations.
• Identify common adverse effects and strategies for their mitigation.
• Recognize special considerations in pregnancy, lactation, pediatrics, geriatrics, and patients with renal or hepatic impairment.

Classification

Drug Classes and Categories

Iron deficiency anemia therapy is broadly divided into two pharmacologic classes based on the route of administration: oral iron salts and intravenous iron complexes. Oral preparations are typically iron (II) salts, while intravenous formulations consist of iron (III) complexes bound to carrier molecules that facilitate safe systemic delivery.

• Oral Iron Salts
  • Ferrous sulfate (FeSO₄)
  • Ferrous gluconate (Fe₂(C₆H₁₁O₇)₂)
  • Ferrous fumarate (Fe₂(C₄H₂O₄)₂)
  • Ferrous fumarate–sucrose complexes
• Intravenous Iron Complexes
  • Iron sucrose (IS) – iron(III) hydroxide complexed with sucrose
  • Ferric carboxymaltose (FCM) – iron(III) carboxymaltose complex
  • Ferric derisomaltose (FDI) – iron(III) isomaltose complex
  • Iron dextran – high-molecular-weight dextran-iron complex

Chemical Classification

Oral iron salts are generally iron(II) compounds that dissociate in the acidic environment of the stomach, releasing ferrous ions for absorption. In contrast, intravenous preparations are iron(III) complexes stabilized by polysaccharide or carbohydrate ligands, thereby preventing precipitation and reducing free iron-mediated oxidative damage. The carbohydrate moiety serves as a stabilizer and facilitates controlled release of iron into the circulation, thereby allowing for higher dosing per infusion.

Mechanism of Action

Pharmacodynamics

Iron therapy restores the deficit of elemental iron required for heme biosynthesis within erythroid precursors. The key pharmacodynamic objectives are to replenish systemic iron stores, enhance erythropoiesis, and ultimately increase hemoglobin concentration and red blood cell mass.

Receptor Interactions

Oral iron absorption is mediated primarily by the divalent metal transporter 1 (DMT1) located on the apical surface of duodenal enterocytes. Iron(II) ions are transported across the enterocyte cytoplasm and subsequently exported into the bloodstream via ferroportin, the sole known iron exporter. Hepcidin, a liver-derived peptide hormone, regulates ferroportin expression by binding and inducing its internalization and degradation, thereby modulating systemic iron availability. Intravenous iron bypasses DMT1-mediated absorption and is taken up by reticuloendothelial macrophages through macropinocytosis and receptor-mediated endocytosis involving transferrin receptor 2 (TfR2) and other iron-binding receptors. Within macrophages, iron is released into the labile iron pool and subsequently exported via ferroportin, following the same hepcidin regulatory pathway.

Molecular and Cellular Mechanisms

Following administration, elemental iron is incorporated into hemoglobin during the maturation of erythroblasts in the bone marrow. The rate of erythropoiesis is influenced by erythropoietin (EPO) stimulation, which is in turn modulated by tissue oxygenation status. Iron deficiency results in reduced activity of 5-aminolevulinic acid synthase (ALAS), the rate-limiting enzyme in heme synthesis. Restoring iron levels reactivates ALAS, allowing efficient heme production and subsequent integration into hemoglobin. Additionally, iron serves as a cofactor for numerous cellular enzymes, including those involved in DNA synthesis and mitochondrial respiration; thus, iron repletion supports overall cellular metabolism.

Pharmacokinetics

Absorption

Oral iron salts are absorbed in the proximal duodenum and proximal jejunum. The absorption efficiency is influenced by gastric pH, presence of concomitant foods or medications, and the body’s iron status. Ferrous sulfate is typically absorbed at a rate of 10–20% of the dose, though the actual bioavailability can vary markedly. Factors such as ascorbic acid coadministration can enhance absorption by reducing ferric to ferrous iron, whereas calcium carbonate, phytates, and polyphenols may inhibit absorption by forming insoluble complexes.

Intravenous iron complexes circumvent gastrointestinal absorption barriers. Following infusion, iron is released in a controlled manner from the carrier complex, allowing gradual entry into the systemic circulation. The release kinetics are governed by the stability of the iron-carbohydrate bond; for example, ferric carboxymaltose releases iron more rapidly compared to iron sucrose, permitting higher single-dose administration.

Distribution

After absorption, elemental iron is bound to transferrin in the plasma, which serves as the primary transport protein. Transferrin-carrying iron is delivered to bone marrow erythroblasts via transferrin receptor-mediated endocytosis. Intravenous iron complexes are initially taken up by the mononuclear phagocyte system, primarily the liver, spleen, and bone marrow macrophages. Within macrophages, iron is stored in ferritin complexes or released into the labile iron pool for systemic distribution.

Metabolism

Both oral and intravenous iron undergo metabolism primarily within the reticuloendothelial system. In macrophages, iron is either incorporated into ferritin for storage or exported via ferroportin. Hepcidin-mediated regulation modulates ferroportin expression, thereby influencing systemic iron release. No significant hepatic metabolism of the iron ion itself occurs; rather, the metabolic fate pertains to the carrier complexes and their carbohydrate ligands, which are metabolized via normal carbohydrate catabolic pathways.

Excretion

Iron is not actively excreted by the kidneys; rather, loss occurs through slow turnover of erythrocytes, shedding of intestinal mucosa, and minor urinary excretion. The rate of iron loss is approximately 1–2 mg per day in healthy adults. Intravenous iron complexes degrade over time, with iron released and recycled; the residual carbohydrate moieties are metabolized and excreted via the biliary and renal routes as applicable.

Half-life and Dosing Considerations

The terminal half-life of elemental iron following oral administration depends on the dosage and individual absorption characteristics but generally ranges from 1 to 4 hours. However, the pharmacodynamic effect, measured as hemoglobin rise, manifests over weeks due to the time required for erythropoiesis and red cell maturation. Intravenous iron complexes exhibit a longer systemic half-life, with ferric carboxymaltose demonstrating a terminal half-life of approximately 20 days owing to its stable complex structure. Dosing regimens are individualized based on iron deficit calculations, typically expressed as total iron deficit = (body weight × (target hemoglobin – actual hemoglobin) × 2.4) + iron stores (500 mg). Intravenous formulations allow for rapid correction of deficits, often with a single infusion, whereas oral therapy requires daily dosing over several weeks to months.

Therapeutic Uses / Clinical Applications

Approved Indications

Iron supplementation is indicated for the treatment of iron deficiency anemia in both adult and pediatric populations. Oral iron salts are approved for mild to moderate IDA, whereas intravenous iron complexes are indicated when oral therapy is contraindicated, poorly tolerated, or ineffective. Specific approved indications include:

• Iron deficiency anemia secondary to chronic blood loss (e.g., gastrointestinal bleeding, menorrhagia).
• Iron deficiency anemia in patients with malabsorption syndromes (celiac disease, inflammatory bowel disease).
• Iron deficiency anemia in pregnant patients when oral therapy fails or is not tolerated.
• Iron deficiency anemia in patients undergoing chemotherapy or radiotherapy, where rapid hematologic recovery is desirable.
• Iron deficiency states in patients with chronic kidney disease undergoing dialysis, when oral iron absorption is limited.

Off-label Uses

Off-label utilization of intravenous iron formulations is common in scenarios such as:

• Patients with severe fatigue and functional impairment where rapid hemoglobin improvement is clinically beneficial.
• Patients with gastrointestinal disorders preventing adequate oral iron absorption (e.g., bariatric surgery).
• Patients with chronic inflammatory conditions where hepcidin-mediated sequestration limits oral iron effectiveness.
• Use of lower-dose intravenous iron in the perioperative setting to reduce blood transfusion requirements.

Adverse Effects

Common Side Effects

Oral iron therapy is frequently associated with gastrointestinal adverse events, including nausea, abdominal discomfort, constipation, and darkened stool. These symptoms may reduce adherence and are often mitigated by taking the medication with food or switching to a different formulation. Intravenous iron preparations exhibit a lower incidence of gastrointestinal symptoms but may cause infusion-related reactions such as flushing, pruritus, or mild hypotension.

Serious/ Rare Adverse Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported with intravenous iron dextran, particularly with high-molecular-weight preparations. Lower-molecular-weight formulations such as ferric carboxymaltose and iron sucrose carry a reduced risk of severe allergic responses. Cardiac arrhythmias or transient changes in serum electrolytes have been observed in patients with underlying cardiovascular disease receiving high-dose intravenous iron. Rare reports of iron overload, particularly in patients with preexisting hereditary hemochromatosis or transfusion-dependent anemias, underscore the importance of monitoring iron indices.

Black Box Warnings

Intravenous iron dextran (high-molecular-weight) carries a black box warning for potentially life-threatening hypersensitivity reactions. Lower-molecular-weight intravenous iron products have not received such warnings but are nonetheless monitored for infusion reactions. Oral iron preparations carry no black box warnings but may warrant caution in patients with known gastrointestinal disorders or hypersensitivity to iron salts.

Drug Interactions

Major Drug-Drug Interactions

Oral iron supplementation may interfere with the absorption of several medications by forming insoluble complexes or by competing for transport pathways. Notable interactions include:

• Calcium-containing antacids, laxatives, and dairy products – reduce iron absorption.
• Phosphonate-containing bisphosphonates – inhibit iron uptake.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) – increase gastrointestinal bleeding risk.
• Certain antibiotics (e.g., tetracyclines, fluoroquinolones) – chelate iron, decreasing drug efficacy.
• Thyroid hormones – may reduce iron absorption.

Intravenous iron preparations may interact with medications that affect iron metabolism or hepcidin levels. For instance, erythropoiesis-stimulating agents (ESAs) used in chronic kidney disease can synergistically increase iron demand, necessitating careful iron monitoring to prevent iron deficiency or overload. Anticoagulants may increase the risk of bleeding, thereby potentially exacerbating iron loss.

Contraindications

Absolute contraindications for oral iron include known iron overload disorders (e.g., hereditary hemochromatosis), acute hemolysis, or active gastrointestinal bleeding where iron may exacerbate mucosal injury. Intravenous iron is contraindicated in patients with a history of severe hypersensitivity reactions to iron-carbohydrate complexes, or in those with active systemic infections where iron may promote bacterial growth. General contraindications include uncontrolled bleeding, severe hepatic or renal impairment without appropriate adjustment, and pregnancy in the first trimester unless clearly indicated.

Special Considerations

Use in Pregnancy / Lactation

Iron deficiency is common in pregnancy due to increased iron demands for fetal development and maternal erythropoiesis. Oral iron supplementation is typically first-line, with doses ranging from 30–60 mg elemental iron daily. Intravenous iron may be considered in cases of intolerable gastrointestinal side effects, poor adherence, or severe anemia (<10 g/dL). Lactating mothers with iron deficiency may also benefit from supplementation; iron is excreted in breast milk, and maternal stores are replenished with appropriate dosing. Careful monitoring of hemoglobin and ferritin levels is advised to avoid iron overload.

Pediatric Considerations

Children with iron deficiency anemia often present with delayed growth and developmental delays. Oral iron formulations are preferred, with dosing calculated based on weight (1–3 mg/kg elemental iron per day). Pediatric formulations, such as ferrous fumarate–sucrose complexes, are available to enhance tolerability. Intravenous iron is reserved for severe cases, malabsorption syndromes, or when oral therapy is not feasible. Monitoring for growth parameters and neurocognitive outcomes is essential in this population.

Geriatric Considerations

Older adults frequently experience iron deficiency due to chronic disease, gastrointestinal bleeding, or reduced dietary intake. Oral iron therapy may be complicated by comorbidities such as renal impairment, polypharmacy, and susceptibility to gastrointestinal side effects. Intravenous iron offers a rapid correction strategy but requires careful assessment of cardiovascular status and potential for infusion reactions. Dose adjustments based on renal function and vigilant monitoring of hemoglobin and iron indices are recommended.

Renal / Hepatic Impairment

In chronic kidney disease (CKD), iron deficiency is a common contributor to anemia of chronic disease. Oral iron absorption is often diminished due to uremic inhibition of DMT1 and elevated hepcidin levels. Intravenous iron, particularly ferric carboxymaltose and iron sucrose, is the preferred modality in CKD to achieve adequate iron stores and support ESA therapy. Hepatic impairment may affect hepcidin synthesis and iron metabolism; thus, dosing adjustments and close monitoring of ferritin and transferrin saturation are warranted. Hepatic dysfunction may also increase the risk of hypersensitivity reactions with intravenous iron, necessitating slower infusion rates and premedication as appropriate.

Summary / Key Points

• Iron deficiency anemia is predominantly treated with oral or intravenous iron preparations depending on severity, tolerance, and absorption status.
• Oral iron salts act by supplying elemental iron for hemoglobin synthesis; absorption is mediated by DMT1 and regulated by hepcidin.
• Intravenous iron complexes circumvent gastrointestinal barriers and are taken up by macrophages, allowing rapid restoration of iron stores.
• Common adverse effects include gastrointestinal upset for oral iron and infusion reactions for intravenous iron; serious hypersensitivity reactions are rare but possible.
• Drug interactions, particularly with antacids, calcium, and certain antibiotics, can impair oral iron absorption; monitoring for interactions is essential.
• Special populations such as pregnant women, lactating mothers, children, the elderly, and patients with renal or hepatic impairment require individualized dosing strategies and vigilant monitoring to optimize therapy while minimizing risks.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.